CoChat
Sign Up
Cited by 47Fatty Acid Research and HealthLipoproteins and Cardiovascular HealthLipid metabolism and disorders

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies

Open access
Ballantyne, Christie M., Bays, Harold E., Braeckman, Rene A., Philip, Sephy, Stirtan, William G., Doyle, Ralph T., Soni, Paresh N., Juliano, Rebecca A.·2016·Journal of Clinical Lipidology
DOI 10.1016/j.jacl.2016.02.008
Open this paper in CoChat — free account

Abstract

BACKGROUND: Apolipoprotein C-III (ApoC-III) regulates lipoprotein and triglyceride (TG) metabolism and may have a causal role in cardiovascular disease. In the Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With an Open-Label Extension (MARINE) and ANCHOR studies, icosapent ethyl, a high-purity prescription eicosapentaenoic acid ethyl ester, reduced TG, and other atherogenic lipid parameters without increasing low-density lipoprotein cholesterol (LDL-C) compared with placebo. OBJECTIVE: To evaluate the effects of icosapent ethyl on plasma ApoC-III levels in patients from 2 phase 3 studies. METHODS: MARINE and ANCHOR were 12-week double-blind studies of icosapent ethyl in adult patients. Patients in MARINE had very high TG levels (≥500 and ≤2000 mg/dL) and patients in ANCHOR had high TG levels (≥200 and <500 mg/dL) despite statin control of LDL-C. This post hoc analysis of MARINE and ANCHOR assessed the median percent change from baseline in plasma ApoC-III levels vs placebo and includes subgroup analyses by statin use/efficacy and median ApoC-III levels. RESULTS: We assessed ApoC-III levels in 148 and 612 patients in the MARINE and ANCHOR studies, respectively. In MARINE, the approved prescription dose of icosapent ethyl (4 g/day) significantly reduced ApoC-III levels by 25.1% (P < .0001) vs placebo. In ANCHOR, icosapent ethyl 4 g/day significantly reduced ApoC-III levels by 19.2% (P < .0001) vs placebo; subanalysis by statin efficacy revealed significant reductions vs placebo in the higher-efficacy and medium-efficacy groups (24.6% and 17.2%, respectively; both P < .0001). CONCLUSION: Icosapent ethyl 4 g/day significantly reduced plasma ApoC-III levels in patients with elevated TGs from the MARINE and ANCHOR studies.

Integrity signals

Registry

Crossref · 10.1016/j.jacl.2016.02.008

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Icosapent ethyl is a highly purified ethyl ester of EPA that improves atherogenic dyslipidemia by reducing TG, TG-rich lipoproteins, and factors involved in their metabolism, without raising LDL-C.

    “Icosapent ethyl (Vascepa; Amarin Pharma Inc., Bedminster, NJ) is a highly purified ethyl ester of EPA, which has been reported to improve atherogenic dyslipidemia characterized by reductions in TG, TG‐rich lipoproteins, and factors involved in their metabolism, without raising LDL‐C.25, 26, 27, 28, 29”

    From Rationale and design of <scp>REDUCE‐IT</scp> : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [28]

  • Icosapent ethyl 4 g/d for 12 weeks in a high-risk population similar to REDUCE-IT with persistent TG elevation after statins resulted in significant reductions in TG and atherogenic lipoproteins, and achieved plasma EPA levels comparable to the 1.8 g/d dosing group in JELIS.

    “Icosapent ethyl 12‐week dosing at 4 g/d in a high‐risk population similar to that within the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE‐IT) who had persistent elevations of TG after treatment with statins resulted in significant reductions in TG and atherogenic lipoproteins,26, 27, 28 as well as comparable plasma EPA levels as the 1.8 g/d dosing group in JEL”

    From Rationale and design of <scp>REDUCE‐IT</scp> : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [28]

  • Studies administering higher-dose EPA suggest additional beneficial effects beyond lipid-lowering that may be unique to EPA relative to other TG-lowering therapies, such as beneficial changes in coronary plaque characteristics, which may lead to reductions in major CV events.

    “Finally, studies administering higher‐dose EPA suggest additional beneficial effects beyond lipid‐lowering that may be unique to EPA relative to other TG‐lowering therapies, such as beneficial changes in coronary plaque characteristics, which may lead to reductions in major CV events.4, 16, 25, 26, 27, 28, 29, 30, 31, 32, 33”

    From Rationale and design of <scp>REDUCE‐IT</scp> : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [28]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ballantyne, C. M., Bays, H. E., Braeckman, R. A., Philip, S., Stirtan, W. G., Doyle, R. T., Soni, P. N., & Juliano, R. A.
Affiliations
  • Houston Methodist (US)
  • Louisville Metabolic and Atherosclerosis Research Center (US)
  • Amarin (United States) (US)
Corresponding author
Ballantyne, Christie M.
ORCID
Venue
Journal of Clinical Lipidology
Publisher
Elsevier BV
Published
2016-05
Volume
10
Issue
3
Pages
635-645.e1
ISSN
  • 1876-4789 (ISSN-L)
  • 1933-2874
DOI
10.1016/j.jacl.2016.02.008
OpenAlex
W2151839802
Cited by
47
References
13
Citations by year
2023: 2 · 2022: 4 · 2021: 5 · 2020: 6 · 2019: 8 · 2018: 4 · 2017: 7 · 2016: 6 · 2015: 2 · 2014: 2
FWCI
8.72
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of clinical lipidology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Amarin Pharma
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
icosapent ethyl, eicosapentaenoic acid ethyl ester, apolipoprotein C-III, hypertriglyceridemia, statin therapy, triglyceride-lowering therapy, omega-3 fatty acids, lipoprotein metabolism, cardiovascular risk
MeSH terms
Female, Humans, Male, Middle Aged, Triglycerides, Eicosapentaenoic Acid, Atherosclerosis, Apolipoprotein C-III

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review